Galantamine for the treatment of cognitive impairments in people with schizophrenia
Abstract
OBJECTIVE: People with schizophrenia are characterized by a broad range of cognitive impairments. Despite appropriate treatment with conventional or second-generation antipsychotics, they continue to exhibit pronounced impairments. The current study was designed to examine the efficacy and safety of galantamine, an acetylcholinesterase inhibitor that also acts as an allosteric modulator at the alpha(4)beta(2) and alpha(7) nicotinic receptors, for the treatment of these impairments. METHOD: Eighty-six people with schizophrenia were entered into a 12-week double-blind, placebo-controlled, randomized clinical trial. Forty-two subjects were assigned to galantamine and 44 were assigned to placebo. The efficacy of galantamine for cognitive impairments was evaluated with neuropsychological measures of attention, motor speed, processing speed, verbal and visual memory, and working memory. RESULTS: The treatment effect for the overall composite score was not significant, but the heterogeneity of treatment effect analysis was significant. Follow-up analyses revealed that the subjects taking galantamine exhibited significant improvements on the WAIS-III digit symbol and verbal memory measures. In contrast, the subjects taking placebo showed a significant improvement on the GDS distractibility test. The group differences on the WAIS-III digit symbol and GDS distractibility test remained significant after correction for multiple comparisons. There were no significant between-group differences in motor speed or working memory. In general, safety analyses revealed that galantamine was well tolerated. CONCLUSIONS: Study results suggest that galantamine may have selective benefits for aspects of processing speed and verbal memory but interferes with practice effects during the performance of an attention task.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Galantamine may have selective benefits for aspects of processing speed and verbal memory but interferes with practice effects during the performance of an attention task.
“• Galantamine may have selective benefits for aspects of processing speed and verbal memory but interferes with practice effects during the performance of an attention task.”
From Clinical trials of potential cognitive-enhancing drugs in schizophrenia: what have we learned so far? (2013) · cites this paper as [39]
In the Buchanan et al galantamine trial, there were significant improvements on the WAIS-III digit symbol and verbal memory measures with galantamine.
“• Significant improvements on the WAIS-III digit symbol and verbal memory measures with galantamine”
From Clinical trials of potential cognitive-enhancing drugs in schizophrenia: what have we learned so far? (2013) · cites this paper as [39]
In the Buchanan et al galantamine trial, there was significant improvement on the GDS distractibility test with placebo.
“• Significant improvement on the GDS distractibility test with placebo.”
From Clinical trials of potential cognitive-enhancing drugs in schizophrenia: what have we learned so far? (2013) · cites this paper as [39]
Cites
Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing
Benjamini, Y., & Hochberg, Y. (1995) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1995.tb02031.x · Cited by 109,482 · see citing works
The Brief Psychiatric Rating Scale.
Overall, J. E., & Gorham, D. R. (1962) · Psychological Reports · doi:10.2466/pr0.1962.10.3.799 · Cited by 11,090 · see citing works
The Fagerstrom Test for Nicotine Dependence: a revision of the Fagerstrom Tolerance Questionnaire
HEATHERTON, T. F., KOZLOWSKI, L. T., FRECKER, R. C., & FAGERSTROM, K. (1991) · British Journal of Addiction · doi:10.1111/j.1360-0443.1991.tb01879.x · Cited by 10,738 · see citing works
Wechsler Adult Intelligence Scale-III
Ryan, J. J., & Lopez, S. J. (2001) · Springer eBooks · doi:10.1007/978-1-4615-1185-4_2 · Cited by 3,680 · see citing works
A RATING SCALE FOR EXTRAPYRAMIDAL SIDE EFFECTS
Simpson, G. M., B., M., B., G., Angus, J. W. S., P., F. R. C., & M., D. P. (1970) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1970.tb02066.x · Cited by 3,265 · see citing works
Negative Symptoms in Schizophrenia: Definition and Reliability
Andreasen, N. C. (1982) · Archives of General Psychiatry · doi:10.1001/archpsyc.1982.04290070020005 · Cited by 2,247 · see citing works
ECDEU Assessment Manual: (591322011-001)
Guy, W. (1976) · PsycEXTRA Dataset · doi:10.1037/e591322011-001 · Cited by 1,896 · see citing works
Keefe, R. (2004) · Schizophrenia Research · doi:10.1016/j.schres.2003.09.011 · Cited by 1,573 · see citing works
Identification of separable cognitive factors in schizophrenia
Nuechterlein, K. H., Barch, D. M., Gold, J. M., Goldberg, T. E., Green, M. F., & Heaton, R. K. (2004) · Schizophrenia Research · doi:10.1016/j.schres.2004.09.007 · Cited by 1,304 · see citing works
Self-citationKeefe, R. S. E. (2007) · Archives of General Psychiatry · doi:10.1001/archpsyc.64.6.633 · Cited by 1,072 · see citing works
Dickinson, D., Ramsey, M. E., & Gold, J. M. (2007) · Archives of General Psychiatry · doi:10.1001/archpsyc.64.5.532 · Cited by 863 · see citing works
Self-citationFreedman, R., Hall, M., Adler, L. E., & Leonard, S. (1995) · Biological Psychiatry · doi:10.1016/0006-3223(94)00252-x · Cited by 678 · see citing works
Proof-of-Concept Trial of an α7 Nicotinic Agonist in Schizophrenia
D, A. O. M., Harris, J. G., Johnson, L. L., Pender, V., Kongs, S., Allensworth, D., Ellis, J., Zerbe, G. O., Leonard, S. S., Stevens, K. E., et al. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.6.630 · Cited by 531 · see citing works
Scott, L. J., & Goa, K. L. (2000) · Drugs · doi:10.2165/00003495-200060050-00008 · Cited by 383 · see citing works
Cholinesterase Inhibitors: A New Class of Psychotropic Compounds
Cummings, J. L. (2000) · American Journal of Psychiatry · doi:10.1176/ajp.157.1.4 · Cited by 383 · see citing works
Samochocki, M., Höffle‐Maas, A., Fehrenbacher, A., Jostock, R., Ludwig, J., Christner, C., Radina, M., Zerlin, M., Ullmer, C., Pereira, E. F. R., et al. (2003) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.045773 · Cited by 345 · see citing works
Abnormal Regulation of High Affinity Nicotinic Receptors in Subjects with Schizophrenia
Breese, C. R. (2000) · Neuropsychopharmacology · doi:10.1016/s0893-133x(00)00121-4 · Cited by 343 · see citing works
Gold, J. M., Queern, C. A., Iannone, V. N., & Buchanan, R. W. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.12.1944 · Cited by 327 · see citing works
Self-citationCholinergic Enhancement and Increased Selectivity of Perceptual Processing During Working Memory
Furey, M. L., Pietrini, P., & Haxby, J. V. (2000) · Science · doi:10.1126/science.290.5500.2315 · Cited by 308 · see citing works
Guan, Z., Zhang, X., Blennow, K., & Nordberg, A. K. (1999) · Neuroreport · doi:10.1097/00001756-199906030-00028 · Cited by 286 · see citing works
Effects of Nicotine on Cognitive Deficits in Schizophrenia
Harris, J. G., Kongs, S., Allensworth, D., Martín, L., Tregellas, J. R., Sullivan, B. F., Zerbe, G. O., & Freedman, R. (2004) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300450 · Cited by 235 · see citing works
Crook, J., Tomaskovic-Crook, E., Copolov, D., & Dean, B. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.6.918 · Cited by 224 · see citing works
In vivo determination of muscarinic acetylcholine receptor availability in schizophrenia.
Raedler, T., Knable, M., Jones, D. W., Urbina, R. A., Gorey, J. G., Lee, K., Egan, M., Coppola, R., & Weinberger, D. (2003) · American Journal of Psychiatry · doi:10.1176/appi.ajp.160.1.118 · Cited by 222 · see citing works
Wechsler Adult Intelligence Scale
Luiselli, J., Happe, F. G. E., Hurst, H., et al. (2012) · Springer eBooks · doi:10.1007/978-1-4419-1698-3_101553 · Cited by 209 · see citing works
Effects of Nicotine Nasal Spray on Cognitive Function in Schizophrenia
Smith, R. C., Warner‐Cohen, J., Matute, M., Butler, E., Kelly, E., Vaidhyanathaswamy, S., & Khan, A. (2005) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300881 · Cited by 182 · see citing works
Wang, D., Noda, Y., Zhou, Y., Mouri, A., Mizoguchi, H., Nitta, A., Chen, W., & Nabeshima, T. (2006) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301256 · Cited by 148 · see citing works
Keefe, R. S. E., Malhotra, A. K., Meltzer, H. Y., Kane, J. M., Buchanan, R. W., Murthy, A. K., Sovel, M., Li, C., & GOLDMAN, R. S. (2007) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301499 · Cited by 146 · see citing works
Self-citationGalantamine Improves Cognition in Schizophrenic Patients Stabilized on Risperidone
Schubert, M., Young, K. A., & Hicks, P. B. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.04.006 · Cited by 140 · see citing works
Schilström, B., Ivanov, V., Wiker, C., & Svensson, T. H. (2006) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301087 · Cited by 128 · see citing works
Conover, W. J., & Salsburg, D. S. (1988) · Biometrics · doi:10.2307/2531906 · Cited by 103 · see citing works
Buchanan, R. W., Summerfelt, A. T., Tek, C., & Gold, J. M. (2002) · Schizophrenia Research · doi:10.1016/s0920-9964(01)00387-5 · Cited by 99 · see citing works
Self-citationCognitive and Behavioral Effects of Cholinergic, Dopaminergic, and Serotonergic Blockade in Humans
Vitiello, B. (1997) · Neuropsychopharmacology · doi:10.1016/s0893-133x(96)00134-0 · Cited by 98 · see citing works
Dajas‐Bailador, F., Heimala, K., & Wonnacott, S. (2003) · Molecular Pharmacology · doi:10.1124/mol.64.5.1217 · Cited by 96 · see citing works
Lee, S.-W., Lee, J.-G., Lee, B. J., & Kim, Y. H. (2007) · International Clinical Psychopharmacology · doi:10.1097/yic.0b013e3280117feb · Cited by 89 · see citing works
SHARMA, T., REED, C., Aasen, I., & Kumari, V. (2006) · Schizophrenia Research · doi:10.1016/j.schres.2006.03.037 · Cited by 79 · see citing works
Ferreri, F., Agbokou, C., & Gauthier, S. G. (2006) · Journal of Psychiatry and Neuroscience · doi:10.1139/jpn.0641 · Cited by 49 · see citing works
McMahon, R. P., Arndt, S. V., & Conley, R. R. (2004) · Statistics in Medicine · doi:10.1002/sim.1837 · Cited by 8 · see citing works
Self-citationWalter, S. D. (1999) · Statistics in Medicine · doi:10.1002/(sici)1097-0258(19990130)18:2
Flagged first, then by citations
Cited by
Sorted by citations
Initial phase 2 trial of a nicotinic agonist in schizophrenia
Freedman, R., Olincy, A., Buchanan, R. W., Harris, J. G., Gold, J. M., Johnson, L., Allensworth, D., Guzman-Bonilla, A., Clement, B., Ball, M. P., et al. (2008) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2008.07071135 · Cited by 426 · see citing works
Self-citationBuchanan, R. W., Keefe, R. S. E., Umbricht, D., Green, M. F., Laughren, T., & Marder, S. R. (2011) · Schizophrenia Bulletin · doi:10.1093/schbul/sbq038 · Cited by 154 · see citing works
Self-citationKeefe, R. S. E., Buchanan, R. W., Marder, S. R., Schooler, N. R., Dugar, A., Zivkov, M., & Stewart, M. (2013) · Schizophrenia Bulletin · doi:10.1093/schbul/sbr153 · Cited by 138 · see citing works
Self-citationAn integrative framework for perceptual disturbances in psychosis
Horga, G., & Abi-Dargham, A. (2019) · Nature Reviews Neuroscience · doi:10.1038/s41583-019-0234-1 · Cited by 103 · see citing works
Leveraging the cortical cholinergic system to enhance attention
Demeter, E., & Sarter, M. (2013) · Neuropharmacology · doi:10.1016/j.neuropharm.2012.06.060 · Cited by 75 · see citing works
Konradsson‐Geuken, Å., Gash, C. R., Alexander, K., Pomerleau, F., Huettl, P., Gerhardt, G. A., & Bruno, J. P. (2009) · Synapse · doi:10.1002/syn.20693 · Cited by 71 · see citing works
Acheson, D. T., Twamley, E. W., & Young, J. W. (2013) · Frontiers in Neuroscience · doi:10.3389/fnins.2013.00103 · Cited by 26 · see citing works
Pharmacological Treatment of Cognitive Dysfunction in Neuropsychiatric Disorders
Venero, C. (2015) · Cognitive Enhancement · doi:10.1016/b978-0-12-417042-1.00010-3 · Cited by 4 · see citing works
- Authors
- Buchanan, R. W., Conley, R. R., Dickinson, D., Ball, M. P., Feldman, S., Gold, J. M., & McMahon, R. P.
- Affiliations
- University of Maryland, Baltimore (US)
- ORCID
- Venue
- American Journal of Psychiatry
- Published
- 2008-01
- Volume
- 165
- Issue
- 1
- Pages
- 82-89
- ISSN
- 0002-953X (ISSN-L)
- 1535-7228
- OpenAlex
- W2165321423
- Cited by
- 170
- References
- 38
- Citations by year
- 2026: 2 · 2025: 5 · 2024: 2 · 2023: 3 · 2022: 2 · 2021: 3 · 2020: 6 · 2019: 8 · 2018: 9 · 2017: 7 · 2016: 10 · 2015: 9 · 2014: 9 · 2013: 14 · 2012: 19
- FWCI
- 9.66
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- American Journal of Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Funders
- U.S. Public Health Service (P30 068580)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nicotinic Acetylcholine Receptors Study
- Keywords
- galantamine, schizophrenia, cognitive impairment, acetylcholinesterase inhibitors, processing speed, verbal memory, attention, distractibility, working memory, motor speed, drug safety
- MeSH terms
- Attention, Cholinesterase Inhibitors, Cognition Disorders, Female, Follow-Up Studies, Galantamine, Humans, Male, Middle Aged, Neuropsychological Tests, Brief Psychiatric Rating Scale, Practice, Psychological, Receptors, Nicotinic, Schizophrenia, Schizophrenic Psychology, Wechsler Scales, Treatment Outcome, Diagnostic and Statistical Manual of Mental Disorders, alpha7 Nicotinic Acetylcholine Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
